Detalhe da pesquisa
1.
Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
Oral Oncol
; 82: 83-90, 2018 07.
Artigo
Inglês
| MEDLINE | ID: mdl-29909907